Foreign Exchange Rates Said To Bode Well For Chinese Pharmas
This article was originally published in PharmAsia News
Executive Summary
Chinese drug makers can expect to benefit by a foreign exchange rate that makes the yuan stronger against the American dollar and other currencies. The situation is expected to lead to greater foreign investments in China's industry and give drug makers greater domestic purchasing power. At the same time, foreign competitors face greater operating costs in China, leading them to expect a greater contribution from alliances with other Chinese firms. The estimates come from Synthetic Organic Chemical Manufacturers Association, a global group for chemical companies. (Click here for more
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.